Mood lability and depression limit oral contraceptive therapy in endometriosis
Cevik E, Taylor H. Mood lability and depression limit oral contraceptive therapy in endometriosis. Fertility And Sterility 2024 PMID: 39672361, DOI: 10.1016/j.fertnstert.2024.12.011.Peer-Reviewed Original ResearchProgestin-only oral contraceptivesOral contraceptivesOC discontinuationOC useDiagnosis of depressionMood labilityEffects of oral contraceptivesOral contraceptive (OCDocumented diagnosis of depressionDiscontinued OC useEffect of OC useInternational Classification of Diseases-10 codesSide effects of OC useElectronic medical record reviewTreated with OCCourse of treatmentMedical record reviewIncreased incidence of depressionUniversity affiliated hospitalTreatment discontinuationIncidence of depressionEndometriosisStudy cohortPrimary outcomeIncreased incidenceVilaprisan for the treatment of symptomatic endometriosis: results from a terminated phase 2b randomized controlled trial
Taylor H, Dong L, Haikonen J, Oppelt P, Tamussino K, Wenzl R, Faustmann T, Groettrup-Wolfers E, Ren X, Seitz C. Vilaprisan for the treatment of symptomatic endometriosis: results from a terminated phase 2b randomized controlled trial. F&S Reports 2024, 5: 189-196. PMID: 38983729, PMCID: PMC11228778, DOI: 10.1016/j.xfre.2024.03.002.Peer-Reviewed Original ResearchPelvic painSymptomatic endometriosisTreatment of symptomatic endometriosisEndometriosis-associated pelvic painBaseline to month 3Use of pain medicationAverage pain scoreMonths of treatmentPhase 2b randomized controlled trialAssess treatment effectsOutcome measures Primary outcomesPlacebo recipientsRandomized controlled trialsPain scoresMonth 3Pain medicationIncreased painVilaprisanPlaceboPrimary outcomeEndometriosisToxicity findingsIntervention participantsClinical relevanceBleeding intensity